Data on patients with T4
gastric cancer who underwent radical gastric resection between March 2016 and August 2017 were collected from the National
Cancer Center and Huangxing Cancer Hospital. Enrolled patients were divided into two groups according to receiving or not receiving
HIPEC.
Results: A total of 106 patients were included in this study; among them, 51 patients underwent radical gastric resection plus prophylactic
HIPEC, and 55 patients underwent radical gastric resection only. The baseline characteristics were well balanced between the two groups. The postoperative platelet counts in the
HIPEC group were significantly lower than those in the non-
HIPEC group (P < 0.05); however, we did not observe any occurrences of serious
bleeding in the
HIPEC group. There were no significant differences in the postoperative complication rates between the two groups (P > 0.05). The postoperative (1 month) CEA, CA19-9, and CA72-4 levels in the
HIPEC group were significantly decreased in the
HIPEC group (P < 0.05). At a median follow-up of 59.3 months, 3 (5.5%) patients in the
HIPEC group experienced peritoneal recurrence, and 10 (18.2%) patients in the non-
HIPEC group experienced peritoneal recurrence (P < 0.05). Both groups had comparable 5-year overall survival (OS) rates (41.1%
HIPEC group vs. 34.5% non-
HIPEC group, P = 0.118). The 5-year disease-free survival was significantly higher in the
HIPEC group than in the non-
HIPEC group (28.6% versus 39.7%, p = 0.046).
Conclusions:
Lobaplatin-based prophylactic
HIPEC is feasible and safe for patients with T4
gastric cancer and does not increase postoperative adverse effects. The use of
HIPEC showed a significant decrease in the incidence of local recurrence rates and blood
tumor marker levels. The 5-year disease-free survival was significantly higher in the
HIPEC group; however, the 5-year OS benefit was not found in T4 stage patients.